Trial Profile
Pregabalin open-label, multicenter add-on trial following a 4-day double-blind transition period to determine long-term safety and efficacy in patients with partial seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2006
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Oct 2006 New trial record.